2024-09-16 - Analysis Report
## ABBV Stock Analysis Report

**Company Overview:** AbbVie Inc. (ABBV) is a global pharmaceutical company specializing in research, development, and commercialization of innovative medicines. 

**Performance Summary:**

**1.  Performance Against Benchmark:**

* **Cumulative Return:** ABBV has generated a cumulative return of 103.61%, outperforming the S&P 500 (VOO) which has yielded 88.73%.
* **Relative Outperformance:** ABBV is currently outperforming the S&P 500 by 14.88% (63.46% relative to the historical range of outperformance). This indicates ABBV has outperformed the S&P 500 for a significant portion of its historical performance.

**2. Recent Price Movement:**

* **Closing Price:** $194.21
* **5-Day Moving Average:** $195.72
* **20-Day Moving Average:** $195.86
* **60-Day Moving Average:** $183.50

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 42.31. The RSI is currently in the neutral range, suggesting neither overbought nor oversold conditions.
* **PPO (Percentage Price Oscillator):** -0.49. The PPO is slightly negative, indicating a possible short-term bearish bias.
* **Delta_Previous_Relative_Divergence:** -2.54. This indicates a recent (20-day) decline in relative outperformance, suggesting potential downward pressure.
* **Expected Return:** 17.29%. This represents the potential maximum return on investment over a 5-year period, assuming current trends continue.

**4. Recent Earnings and Outlook:**

| Date       | EPS    | Expected EPS |
|------------|--------|--------------|
| 2024-07-25 | 2.65   | 2.57          |
| 2024-04-26 | 2.31   | 2.26          |
| 2024-02-02 | 2.79   | 2.76          |
| 2023-10-27 | 2.95   | 2.86          |
| 2023-07-27 | 2.91   | 2.79          |

The most recent earnings for the quarter ending July 25, 2024, came in at $2.65, exceeding the expected EPS of $2.57. ABBV has consistently outperformed earnings estimates in recent quarters, demonstrating strong revenue and profit growth. This positive earnings trend suggests continued growth potential for the company.

**Overall Analysis:**

ABBV has historically outperformed the S&P 500, demonstrating resilience and growth potential. Recent earnings results have been positive, exceeding expectations, and contributing to the company's overall strong performance. However, recent technical indicators suggest a potential short-term bearish bias. While the expected return is positive, it's crucial to monitor the price action and technical indicators closely for potential shifts in trend. 
